Science & Innovation 2014: Foresighting Trajectories for Advanced Innnovative Technologies

1

Foresighting Trajectories for Advanced Innovative Technologies

Professor Joyce Tait (Edinburgh)Professor Joanna Chataway (RAND, OU) Dr Michele Mastroeni (RAND, Edinburgh)

2

Foresighting Future Value Chains

Professor Joyce Tait

3

4

Innovation Ecosystem

Business Model 5

Business Model 4

Business Model 3

Business Model 2

Business Model 1Value Chain

Regulation

Regional Innovation

Policy

Scenario 2

Stakeholderengagement

IP Regimes

Conceptual scenarios

(STRATIS)

(AGIT) (RISE)(CSE)

Quantitative scenarios

Funding Models

RRI

Markets

5

6

[email protected]

Joanna Chataway

Perspectives on public private partnerships health innovationA focus on the SGC

Health innovation public private partnerships are growing in number, diversifying in nature and are a major feature of the policy landscape

UK Life Science Strategy put partnerships and collaborations at the heart of government policy:

Strategy for UK Life Sciences: Building a Life Sciences Ecosystem

Innovation Health and Wealth: Accelerating adoption and diffusion in the NHS (includes opening up NHS patient data)

TSB and research councils working to promote partnership

Public private partnerships: a growing phenomenon

SGC at a glance

A public private partnership that supports the discovery of medicines through open access research

Based in Oxford and Toronto, operating since 2004

Funded by Wellcome Trust, Canadian government, and 9 leading pharma companies, 20M $/year currently

Open Access Policy Promptly placing results, reagents and know-how in the public

domain (no patents)

SGC’s open innovation model in early stage drug discovery

Public-PrivatePartnership

Public Domain Proprietary

Tools & Basic Knowledge

Discovery and Exploration

Drug Discovery andDevelopment

Facilitated by access to increased amount of information in the public domain

Weigelt J. EMBO Reports 10:941-5 (2009)

SGC’s knowledge production

1564

protein structures deposited in the

Protein Data Bank

654peer reviewed publications

128biological probes

19epigenetic chemical probes

SGC as a model for investing in knowledge with multiple incentives for investment

Open access Collaborative research

opportunities

De-risk emerging areas of science

Linking with strategic initiatives

Rapid and efficient research

processes

De-risking new areas of protein structure science

However there are disincentives to investment

Unprotected intellectual property (private sector)

Limited opportunities for spillover effects (public sector)

However there are disincentives to investment

Unprotected intellectual property (private sector)

Limited opportunities for spillover effects (public sector)

‘The SGC needs to show evidence of wider benefits in the form of economic benefits, spillovers and encouraging investment. The science is good but the SGC hasn’t catalysed the development of a cluster in the way [we] hoped.’

SGC specific conclusions

The SGC is successful and should be maintained

The public sector:Ensures open accessAllows the SGC to remain innovative

The private sector:Provides the SGC’s industrial edge, making it efficient and effective

Thinking more broadly…. Open access platforms shown to be viable in the pharmaceutical

sector but the question is will open access challenge existing conventions more broadly

This model challenges pre-conceived ideas about the way health research and pharma actors must work together

Social technology experiments that bridge public and private sectors in new ways may be important to the future of drug discovery but will they and should they challenge broader institutional norms?

Do we need to think harder about what sorts of partnerships are appropriate for different contexts and objectives? What kind of research do we need to determine this? An RoI study that looks at the advantages and disadvantages of open access against IP based pathways in different contexts?

[email protected]

20

Mission-Oriented Research

Pulling together to overcome obstacles

Michele Mastroeni, RAND Europe

21

Difficulties of bringing innovation forward

Many of the problems are not technical; they may be social, political or economic

These are important issues because some of the innovations are meant to offer solutions to serious problems faced by society

How can the key organizations and actors be encouraged to pull together to deliver socially beneficial innovation?

22

Missions or Grand Challenges

Some have called for a return to mission-oriented research to overcome some of these problems; but must address: Interdisciplinarity Cross-departmental coordination and

coherence Multi-level governance Technology convergence or fusion Cross-sector collaboration Long-term time horizons

23

Innogen Approach

A meta-heuristic that creates an air of collaboration and willingness to spot and work through issues that need addressing

Need to determine how to: Narrow and define broad challenges to

allow for realistic efforts Identify and involve different

stakeholders Identify and influence that institutional

changes necessary

24

[email protected]

25

www.innogen.ac.uk

For further details, please contact Elisabeth Barlow at [email protected]